Market Cap 1.74B
Revenue (ttm) 714.73M
Net Income (ttm) 145.49M
EPS (ttm) N/A
PE Ratio 9.55
Forward PE 9.40
Profit Margin 20.36%
Debt to Equity Ratio 0.22
Volume 708,014
Avg Vol 865,188
Day's Range N/A - N/A
Shares Out 57.53M
Stochastic %K 97%
Beta 0.79
Analysts Strong Sell
Price Target $43.91

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 539 9800
Address:
630 West Germantown Pike, Suite 215, Plymouth Meeting, United States
Invest2live
Invest2live Oct. 24 at 9:59 PM
$GOSS 164% in 10 months. Congratulations 🎊 🎉🎈 Check out $HRMY and $GOVX; excellent value
1 · Reply
Invest2live
Invest2live Oct. 24 at 5:20 PM
$AMD 47% already; congrats 🎈🌿🎉 Check out $AMZN and $TTD as well as $HRMY and $PINS
0 · Reply
Invest2live
Invest2live Oct. 23 at 4:07 PM
$NVDA 1288% already; congrats 🎊 🎉🎈 Check out $TTD and $HRMY; excellent value at these levels. Don’t miss life time opportunity after your DD.
0 · Reply
Invest2live
Invest2live Oct. 23 at 4:05 PM
$HRMY 8% already; congrats 🎈 🌿🎊 Accumulate below 30 after your DD. This has long way to go for longs.
0 · Reply
v2social
v2social Oct. 23 at 2:09 PM
0 · Reply
AlarmedSheiky
AlarmedSheiky Oct. 23 at 1:51 PM
$HRMY Glad I’ve been buying this hand over fist. It still has a looong way to climb
1 · Reply
StocktwitsNews
StocktwitsNews Oct. 23 at 12:35 PM
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? $HRMY $AVUS $SFLO https://stocktwits.com/news/equity/markets/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG
0 · Reply
MahiMe
MahiMe Oct. 23 at 12:09 PM
$HRMY $HRMY Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance https://www.stocktitan.net/news/HRMY/harmony-biosciences-preannounces-strong-q3-2025-wakix-performance-lao4hlxc2yyw.html
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 20 at 1:00 PM
This is not investment advice because $SNDX has a 10/25/2025 PDUFA date (this week) for its Revuforj in mNPM1 leukemias. Should the FDA issue SNDX a CRL SNDX's share price could meaningfully fall. Yes we post data on SNDX more than any other commercial-stage oncology focused bio. This is because traditional valuation metrics suggest SNDX trades at material discounts versus peers. Attached is a list of the FY2029 revenue multiple of SNDX versus every commercial-stage non-oncology focused peer with a market cap between $1.X & $2.5B sorted by FY29 multiple (where more than 1 analyst provides a FY29 estimate). Note SNDX trades at the lowest multiple of FY2029 analyst estimates versus this peer group. We therefore suspect, SHOULD THE FDA APPROVE SNDX's SUBMISSION, SNDX may be undervalued. The only non-oncology focused peer excluded was $HRMY which trades at a lower FY29 multiple, we assume, due to an imminent patent cliff. Even $SRPT trades at a higher multiple. $ARDX $BCRX
4 · Reply
Broview
Broview Oct. 17 at 5:00 AM
$HRMY pay dividend please
0 · Reply
Latest News on HRMY
3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 12 days ago

3 Biotech Stocks I Am Accumulating

ADMA INCY SNDX XBI


Harmony Biosciences: A Compelling Risk-Reward Opportunity

Mar 24, 2025, 12:09 PM EDT - 7 months ago

Harmony Biosciences: A Compelling Risk-Reward Opportunity


Invest2live
Invest2live Oct. 24 at 9:59 PM
$GOSS 164% in 10 months. Congratulations 🎊 🎉🎈 Check out $HRMY and $GOVX; excellent value
1 · Reply
Invest2live
Invest2live Oct. 24 at 5:20 PM
$AMD 47% already; congrats 🎈🌿🎉 Check out $AMZN and $TTD as well as $HRMY and $PINS
0 · Reply
Invest2live
Invest2live Oct. 23 at 4:07 PM
$NVDA 1288% already; congrats 🎊 🎉🎈 Check out $TTD and $HRMY; excellent value at these levels. Don’t miss life time opportunity after your DD.
0 · Reply
Invest2live
Invest2live Oct. 23 at 4:05 PM
$HRMY 8% already; congrats 🎈 🌿🎊 Accumulate below 30 after your DD. This has long way to go for longs.
0 · Reply
v2social
v2social Oct. 23 at 2:09 PM
0 · Reply
AlarmedSheiky
AlarmedSheiky Oct. 23 at 1:51 PM
$HRMY Glad I’ve been buying this hand over fist. It still has a looong way to climb
1 · Reply
StocktwitsNews
StocktwitsNews Oct. 23 at 12:35 PM
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? $HRMY $AVUS $SFLO https://stocktwits.com/news/equity/markets/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG
0 · Reply
MahiMe
MahiMe Oct. 23 at 12:09 PM
$HRMY $HRMY Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance https://www.stocktitan.net/news/HRMY/harmony-biosciences-preannounces-strong-q3-2025-wakix-performance-lao4hlxc2yyw.html
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 20 at 1:00 PM
This is not investment advice because $SNDX has a 10/25/2025 PDUFA date (this week) for its Revuforj in mNPM1 leukemias. Should the FDA issue SNDX a CRL SNDX's share price could meaningfully fall. Yes we post data on SNDX more than any other commercial-stage oncology focused bio. This is because traditional valuation metrics suggest SNDX trades at material discounts versus peers. Attached is a list of the FY2029 revenue multiple of SNDX versus every commercial-stage non-oncology focused peer with a market cap between $1.X & $2.5B sorted by FY29 multiple (where more than 1 analyst provides a FY29 estimate). Note SNDX trades at the lowest multiple of FY2029 analyst estimates versus this peer group. We therefore suspect, SHOULD THE FDA APPROVE SNDX's SUBMISSION, SNDX may be undervalued. The only non-oncology focused peer excluded was $HRMY which trades at a lower FY29 multiple, we assume, due to an imminent patent cliff. Even $SRPT trades at a higher multiple. $ARDX $BCRX
4 · Reply
Broview
Broview Oct. 17 at 5:00 AM
$HRMY pay dividend please
0 · Reply
StockHunter75
StockHunter75 Oct. 15 at 7:15 PM
$HRMY Buying more.
0 · Reply
BigDaddyCapital
BigDaddyCapital Oct. 15 at 4:23 PM
$HRMY whoever is covering UBS is a moron.
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 3:27 PM
UBS has updated their rating for Harmony Biosciences Hldgs ( $HRMY ) to Buy with a price target of 43.
0 · Reply
Quantumup
Quantumup Oct. 15 at 11:16 AM
UBS⬇️ $HRMY's PT to $43 from $50/⬇️'29 sales ests to $1.08B from $1.34B on Wakix competitive pressures in the NT1/NT2 mkt from pot'l orexin agonists launch. $TAK $ALKS $CNTA ESALY NLSP JAZZ AXSM AVDL UBS said in its note to investors: Based on our buy-side conversations, investors are concerned as HRMY's opportunity to grow into a multi-asset company dwindled with the recent Zygel Ph3 FXS failure (and IH approval rejection). Moreover, it is likely that HRMY's base business Wakix will face competitive pressure in the narcolepsy market with potential orexin agonists launch. We lower our PT to $43 (from $50) based on an unchanged 2.75x multiple on lower 2029E sales of $1.08BN (from $1.34BN) due to the potential competition on Wakix sales and zeroed out Zygel sales. Our PT is supported by DCF.
0 · Reply
Invest2live
Invest2live Oct. 14 at 3:10 PM
$NAK 524% already; congrats 🎈 🎉🎊 Checkout $CLYM and $HRMY
0 · Reply
Invest2live
Invest2live Oct. 14 at 1:48 PM
$GNPX 14% already; congrats 🎈 🎊🎉 Movement in the correct direction. Checkout $HRMY and $CUE
1 · Reply
Invest2live
Invest2live Oct. 13 at 8:17 PM
$DELL 37% already; congrats 🎊 🎉🎈 Checkout $TTD and $HRMY
1 · Reply
Invest2live
Invest2live Oct. 13 at 7:11 PM
$EME 195% already; congrats 🎊 🎉🎈 Checkout $TTD and $HRMY; similar potential
0 · Reply
Invest2live
Invest2live Oct. 11 at 3:11 PM
$MO 57% already; congrats 🎈 🎊🎉 checkout $TTD and $HRMY; excellent value.
1 · Reply
LetchurWinnersRun
LetchurWinnersRun Oct. 10 at 1:58 PM
$HRMY New to this one and beginning due diligence. Why so apparently undervalued?
1 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:39 PM
Keep a close watch on CMCT! $LRMR $UBS $CE $HRMY Y
0 · Reply
BigDaddyCapital
BigDaddyCapital Oct. 7 at 12:47 PM
$HRMY unless they are going to be acquired. Could be likely
0 · Reply